Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.1B
49M shares
52-week range
$15.86 – $50.81
74% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
11.1
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
www.urogen.comNo one on the platform currently holds URGN.
No tracked institution reports a position in URGN as of their last filing.
No one on the platform has traded URGN yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 21.4% | 56.2% | ||||
| Profit Margin % | -139.8% | -161.0% | -59300.2% | |||
| Free Cash Flow Margin % | -148.2% | -132.6% | -40137.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $322M | +188.0% | $-0.22 | $-0.93–$0.22 | — | 6 |
| 2027 | $541M | +68.1% | $2.51 | $0.76–$4.78 | 16.6× | 6 |
| 2028 | $670M | +23.7% | $4.96 | $3.47–$7.84 | 8.4× | 5 |
| 2029 | $832M | +24.2% | $6.76 | $5.78–$8.61 | 6.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.27 | $-0.28 | -5.7% |
| 2026-05-06 | $-0.56 | $-0.47 | +16.1% |
| 2026-03-02 | $-0.52 | $-0.54 | -4.2% |
| 2025-11-06 | $-0.72 | $-0.69 | +4.2% |
| 2025-08-07 | $-0.82 | $-1.05 | -28.0% |
| 2025-05-12 | $-0.83 | $-0.92 | -10.8% |
| 2025-03-10 | $-0.69 | $-0.80 | -15.9% |
| 2024-11-06 | $-0.84 |
| $-0.55 |
| +34.5% |
| $1.6B |
| — |
| NRIXNurix Therapeutics, Inc. | $24.83 | -2.70% | $2.6B | — |
| OCSOculis Holding AG | $10.07 | -5.00% | $576M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$URGN should be able to get a buy in around mid to low 30s in the next couple days I would think. Would be a great long hold at that price
View on StockTwits ↗
$URGN is expected to turn profitable in 2027. It keeps riding its rising 10-week moving average.
View on StockTwits ↗
Piper Sandler reiterated $TYRA Overweight-Top Pick-$56 and said -- Dabo IR NMIBC Readout on Wednesday $CGON $URGN JNJ TARA ENGN IBRX Piper Sandler added—We remain OW rated on TYRA shares ahead of proof-of-concept data for lead asset dabogratinib (selective FGFR3 inhibitor) in IR NMIBC, which is slated for disclosure the morning of Wednesday, September 9. As we've discussed previously (see data preview and here), we see the bar for success at this update as a 70% 3-month CR rate with relatively clean safety, which would facilitate advancement into a P3 trial in this setting. Supported by KOL work, we think an effective oral option would be highly differentiated in IR NMIBC, providing a welcome alternative to procedure-based, intravesical options that are currently offered, and model IR NMIBC (intermediate risk non-muscle invasive bladder cancer) as a >$1B opportunity for dabogratinib. TYRA remains one of our 2026 top picks, and we remain buyers into this data event.
View on StockTwits ↗
$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-pharma-present-upcoming-investor-conferences-7
View on StockTwits ↗
$URGN to me this looks like a retrace similar to May. Hopefully. All looks good for this company still
View on StockTwits ↗
$URGN UroGen Pharma stock hub: the UGN-103 NDA is filed, the IntraGel option deal, and a chief medical officer sale that was not under a 10b5-1 plan https://www.merlintrader.com/urogen-pharma-urgn-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=urogen-pharma-urgn-stock-hub
View on StockTwits ↗
FRI 8/28: $URGN – SELLING (ALL) @ $44.61 | P/L: -$545.48 -10.9% 9:44 AM – Selling the back half of my URGN position here this morning and exiting the stock completely. After first breaking below the 10 DMA on 8/20, which triggered our 1ST SELL SIGNAL, shares are now falling below the ROUND-$45 level while the 10 DMA continues to roll over. Those are additional bearish technical signs, and I’m not willing to ignore the continued deterioration. James’ Trader’s Tip: Weakness Often Builds in Stages • The initial break below the 10 DMA was the first warning that short-term momentum had changed. • Losing the ROUND-$45 level adds another technical violation. • A rolling-over 10 DMA reinforces the bearish trend and supports getting completely out when weakness continues to build. https://buyingbreakouts.com/fri-8-28-urgn-selling-all-44-61-p-l-545-48-10-9/
View on StockTwits ↗
$URGN Good levels to buy here at 46 and below.
View on StockTwits ↗
$URGN They have experience in gel like medicines, so this to me seems like a decent shot at coming up with some new products at a not crazy price. I like it.
View on StockTwits ↗$URGN looks like a red day for bios all around. Still
View on StockTwits ↗$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-announces-strategic-collaboration-and-investment
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.